MRI-Guided Radiation Therapy Bests CT Guidance for Prostate Cancer
Benefits seen for genitourinary and gastrointestinal toxic effects
Benefits seen for genitourinary and gastrointestinal toxic effects
An international panel weighed in on management controversies in intermediate- and high-risk and locally advanced prostate cancer.
Black cancer patients are less likely than their White counterparts to receive shorter radiotherapy regimens, a study suggests.
A review of the relationship between cancer, pain, pain management, and radiotherapy.
Radiation therapy for prostate cancer is significantly associated with more than twice the risk for bladder cancer compared with radical prostatectomy, a study found.
Trimodal therapy for bladder cancer results in a slight decline in eGFR in the first year but stabilizes thereafter for up to 10 years, a study found.
A second course of stereotactic body radiation therapy (SBRT) is an important therapeutic strategy to consider for men with recurrent oligometastatic prostate cancer after an initial course of SBRT, according to investigators.
This is the first study to assess the role of metastasis-directed therapy in solitary metastatic oligorecurrent prostate cancer in the absence of systemic therapy.
Investigators reported findings from the first randomized trial to evaluate the use of metastasis-directed therapy with hormone therapy in patients with oligometastatic prostate cancer.
Benefits may include decreased anxiety, increased technical and overall satisfaction